Zook Anthony P.

NEO CEO Zook buys 17,900 shares at $5.58; stock down -70.5% from $18.61 high, company unprofitable with -$45.1M net income.

Anthony P. Zook, the Chief Executive Officer of NeoGenomics, purchased 17,900 shares at $5.58 on 2025-08-06, increasing his holdings by 88.8% to 38,066 shares. The stock is currently trading at $5.49, down 30-day change of -24.9% and 90-day change of -32.5%, and is -70.5% from its 52-week high of $18.61. Critically, NeoGenomics is unprofitable with net income of -$45.1M against revenue of $181.3M, representing a company facing operational challenges. Zook's prior buy at this ticker on 2025-05-06 delivered negative 90-day returns (-28.0%), establishing a pattern where his equity purchases have not been advantageously timed; this transaction occurs during continued stock deterioration and warrant scrutiny of whether CEO capital deployment reflects conviction in a turnaround or other factors.

CEO Zook buys 18,900 NEO shares at $7.88; 4 other insiders bought within 14 days as stock down -39.6% in 90 days

CEO Anthony P. Zook initiated a position in NEO with a $148,918.77 purchase at $7.88 per share, while the stock has declined -39.6% over 90 days and trades -56.3% below its 52-week high of $18.61. This transaction is notable for the clustering signal: 4 other insiders also purchased within the prior 14 days, suggesting coordinated conviction at current depressed valuations. The buy occurs despite the company reporting negative net income of $-25,923,000.00 in the latest quarter, though revenue growth remains positive at +11.6% year-over-year. The concurrent buying by multiple insiders during a steep drawdown warrants attention to whether management views the decline as an opportunity or faces external pressure to demonstrate confidence.